
Surmodics (SRDX) Stock Forecast & Price Target
Surmodics (SRDX) Analyst Ratings
Bulls say
Surmodics Inc. is actively enhancing its whole-products solutions strategy, which should facilitate accelerated revenue growth in the future. The establishment of a direct sales force to promote its Pounce thrombectomy and Sublime radial access products is expected to strengthen market presence and drive performance. Although the company's operating expenses have increased due to these investments, the potential for future revenue growth in the Medical Device segment remains a key positive factor for the overall outlook.
Bears say
Surmodics Inc is facing significant challenges within its Medical Device segment, primarily due to declining sales of the SurVeil drug-coated balloon, which has resulted in expectations of further revenue decreases in FY25. The company reports lower license fee revenues and decreased sales to its distributor Abbott, contributing to a negative outlook. Additionally, a drop in coating royalty and license fee catch-up payments exacerbates the financial headwinds facing Surmodics, highlighting a potential downturn in overall growth prospects.
This aggregate rating is based on analysts' research of Surmodics and is not a guaranteed prediction by Public.com or investment advice.
Surmodics (SRDX) Analyst Forecast & Price Prediction
Start investing in Surmodics (SRDX)
Order type
Buy in
Order amount
Est. shares
0 shares